TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19
Author:
Funder
Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University
Publisher
Elsevier BV
Subject
General Chemical Engineering,General Chemistry
Reference49 articles.
1. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs;Anand;Science,2003
2. Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine–promising therapeutic strategy for SARS-CoV-2 treatment;Ansari;Exp. Opin. Drug Deliv.,2020
3. Cell-penetrating peptides: 20 years later, where do we stand?;Bechara;FEBS Lett.,2013
4. Toward the estimation of the absolute quality of individual protein structure models;Benkert;Bioinformatics,2011
5. A SARS-CoV-2 vaccine candidate: In-silico cloning and validation;Bhattacharya;Inf. Med. Unlocked,2020
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants;Drugs and Drug Candidates;2024-01-05
2. COVID-19 mitigation: nanotechnological intervention, perspective, and future scope;Materials Advances;2023
3. De novodesign of a stapled peptide targeting SARS-CoV-2 spike protein receptor-binding domain;RSC Medicinal Chemistry;2023
4. Microwave assisted synthesis of 2-amino-4-chloro-pyrimidine derivatives: Anticancer and computational study on potential inhibitory action against COVID-19;Arabian Journal of Chemistry;2022-12
5. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins;Current Pharmaceutical Design;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3